Cardiovascular Disease Management in Rural and Underserved Communities: Increasing Recognition, Individualizing Targets, and Tailoring Treatment

Released On
February 28, 2022

Expires On
February 28, 2023

Media Type

Completion Time
60 minutes

Cardiology, Endocrinology, Geriatric Medicine, Hospitalist, Primary Care

Acute Coronary Syndrome, Acute Heart Failure, Acute Myocardial Infarction, Cardiovascular Disease, Diabetes, Geriatric Medicine, Heart, Heart Disease

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by the Endocrine Society, Postgraduate Institute for Medicine, and RME Collaborative.


This online program is recorded content from the live session at the 3rd Annual Rural Health Clinical Congress and co-supported by independent medical education grants from AbbVie, Inc.; AstraZeneca Pharmaceuticals; Eisai, Inc.; Genentech, a member of the Roche Group; Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc.; Novartis Pharmaceutical Corporation; and Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is supported by independent medical education grants from Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc.; and Novartis Pharmaceuticals Corporation.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit
  • Physicians — 1.0 ABIM MOC Point
  • Nurses — 1.0 Contact Hour (0.5 contact hour of pharmacotherapy credit)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed specifically for primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.

Program Overview

Cardiovascular disease (CVD), the leading cause of death in the United States, disproportionately burdens rural communities. Broadly, rural residents experience higher rates of CVD and CVD-associated mortality compared with their urban counterparts. These disparities are largely driven by challenges surrounding access to care that result from healthcare workforce shortages, long travel distances, and transportation barriers. This CME/CE activity will use a case-based approach to review guideline recommendations on assessment and management of cardiovascular risk and new treatment options for advanced heart failure. Strategies to overcome barriers and improve multidisciplinary care of CVD in rural and underserved areas will also be discussed.

This enduring activity is a recorded session from the 3rd Annual Rural Health Clinical Congress that took place on November 20, 2021.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Implement evidence-based assessment strategies to improve the early recognition and diagnosis of heart failure
  • Evaluate evolving treatment approaches for the management of patients with dyslipidemia and heart failure
  • Select appropriate treatment for patients with cardiovascular disease based on the latest guideline recommendations, clinical evidence, and patient characteristics
  • Discuss strategies for reducing disparities and improving access to cardiology care for patients in rural and underserved areas



Akshay S. Desai, MD, MPH

Associate Professor
Harvard Medical School
Director, Cardiomyopathy and Heart Failure Program
Brigham and Women’s Hospital
Boston, MA


Dana E. King, MD (Moderator)

Clinical Provider
Atrium Health, Wake Forest Baptist
Winston-Salem, NC

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Endocrine Society and Postgraduate Institute for Medicine. Endocrine Society is accredited by the ACCME to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

Physician Continuing Medical Education

The Endocrine Society designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

ABIM MOC Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine's (ABIM) maintenance of certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For physicians claiming ABIM MOC points, your information will be shared through the ACCME’s Program and Activity Reporting System (PARS). Please allow approximately 30 days for your MOC points to appear on your ABIM records.

Continuing Nursing Education

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RME Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Statement of Independence

As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society.

Disclosure Policy

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.


The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Akshay S. Desai, MD, MPH, has disclosed the following relationships: grant/research support from Abbott, Alnylam Pharmaceuticals, Inc., AstraZeneca Pharmaceuticals, Bayer Corporation, and Novartis Pharmaceuticals Corporation; and consultant for Abbott, Alnylam Pharmaceuticals, Inc., Amgen, Inc., AstraZeneca Pharmaceuticals, Bayer Corporation, Biofourmis, Inc., Boehringer-Ingelheim, Boston Scientific Corporation, Cytokinetics, Inc., DalCor Pharmaceuticals, Lexicon Pharmaceuticals, Inc., Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., Relypsa, Inc., Sun Pharmaceutical Industries, Ltd., and Verily Life Sciences.

Dana E. King, MD, has no relevant financial relationships to disclose.

Planners, Managers, and Reviewers

The staff involved in the development of this CME activity reported no relevant financial relationships.

Instructions for Participation and Credit

This activity is offered at no cost to participants. To receive CME/CE credit participants must:

  1. Read the CME/CE information, including learning objectives and disclosure statements.
  2. Complete the pre-test.
  3. View the online activity.
  4. Complete the post-test and evaluation form.

A post-test score of 75% or higher is required to obtain credit. Your certificate will be made available for immediate download.

For Physicians Claiming ABIM MOC Credit
To obtain MOC credit, you must provide your ABIM number and DOB (MM/DD) in the activity evaluation form.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above


The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.

Use of professional judgment:
The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

Drugs and dosages:
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

Policy on Unlabeled/Off-Label Use

The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

Privacy and Confidentiality Statement

The Endocrine Society will record learner's personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

Contact Information

General Questions
For general information or questions about this activity, please contact RME Collaborative at 800-913-9370 or

Accreditation Support
For questions regarding the certification of this activity, please contact the Endocrine Society at (physician credit) or the Postgraduate Institute for Medicine at (nursing credit).

©RME Collaborative, a division of Talem Health, LLC 2022. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.